Trial Profile
Hydromorphone OROS in Korean Cancer Patients: Evaluation of Its Clinical Usefulness in Improvement of Sleep Disturbance.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2013
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Janssen
- 23 Aug 2013 Primary endpoint amended as reported by ClinicalTrials.gov.
- 07 Oct 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2008 Planned initiation date changed to 1 Oct 2009 as reported by ClinicalTrials.gov.